The company abandons TNG908, but is still all in on the troubled target.

Reports of Arc-10's failure are greatly exaggerated, the company argues.

An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.

Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.

After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.